Conferences - Results from #8220

SIU Congress 2016: New therapies and diagnoses in bladder cancer: changing landscape of systemic therapy - Session Highlights October 21, 2016

SIU Congress 2016: New therapies and diagnoses in bladder cancer: Emerging strategies in treatment of BCG unresponsive NMIBC - Session Highlights October 21, 2016

SIU Congress 2016: New therapies and diagnoses in bladder cancer: Optimal use of novel biomarkers and detection strategies for bladder cancer - Session Highlights October 21, 2016

SIU Congress 2016: : Focal therapy for prostate cancer EXPERT REVIEW - Session Highlights October 21, 2016

SIU Congress 2016: Shifting Sands: Testicular cancer: Indication for organ-sparing surgery in testicular lesions - Session Highlights October 21, 2016

SIU Congress 2016: Shifting Sands: Testicular Cancer: High dose chemotherapy necessary for intermediate prognosis NSGCT? - Session Highlights October 21, 2016

SIU Congress 2016: Shifting Sands: Testicular Cancer: Revival of surgery in stage I NSGCT - Session Highlights October 21, 2016

SIU Congress 2016: Debate: T2 and T3a bladder cancer: neoadjuvant chemotherapy should be standard - Session Highlights October 21, 2016

SIU Congress 2016: Using pathway analysis and metabolic signature to predict survival in MIBC - Session Highlights October 21, 2016

SIU Congress 2016: Unmet needs in upper tract TCC - Session Highlights October 21, 2016

SIU Congress 2016: Immunotherapy for advanced urothelial cancer - Session Highlights October 21, 2016

SIU Congress 2016: Urothelial cancer: Controversies in the management of urethral cancer - Session Highlights October 21, 2016

SIU Congress 2016: Chemotherapy should precede AR targeted agents for castrate-resistant metastatic disease in young patients - Session Highlights October 21, 2016

SIU Congress 2016: Kidney Cancer, SRMs treatment should be managed with surgical excision - Session Highlights October 20, 2016

SIU Congress 2016: Localized prostate cancer, Prostate biomarkers are ready for prime time in routine detection of prostate cancer - Session Highlights October 20, 2016

SIU Congress 2016: Localized prostate cancer, The utility of prostate biomarkers for routine clinical practice has not been established - Session Highlights October 20, 2016

SIU Congress 2016: Imaging, biomarkers and new therapies, Debate: MRI can replace prostate biopsy in men with elevated PSA - Session Highlights October 20, 2016

SIU Congress 2016: Controversies in prostate cancer: The new Gleason grade scoring system: implications for decision making - Session Highlights October 20, 2016

SIU Congress 2016: Kidney Cancer, SRMs should be managed with ablation rather than surgery - Session Highlights October 20, 2016

SIU Congress 2016: Kidney Cancer, Biopsy should not be routinely performed - Session Highlights October 20, 2016

Page 412 of 507